-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Characterization of early tau deposition in preclinical Alzheimer's disease (AD) patients is critical for prevention trials aimed at selecting individuals at risk for AD and halting disease progression
Characterization of early tau deposition in preclinical Alzheimer's disease (AD) patients is critical for prevention trials aimed at selecting individuals at risk for AD and halting disease progression
To evaluate the prevalence of cortical tau positron emission tomography (PET) heterogeneity with elevated beta-amyloid (A+) in a large clinically accessible cohort of older adults, experts from Stanford University conducted a A cross-sectional study examining pre-randomization tau PET, amyloid PET, structural magnetic resonance imaging, demographics and cognition from the Anti-Amyloid Therapy (A4) study in asymptomatic AD from April 2014 to December 2017 data
Subsequent analyses used observational tau PET data from the ADNI, HABS, and Wisconsin studies to assess agreement
Subsequent analyses used observational tau PET data from the ADNI, HABS, and Wisconsin studies to assess agreement
RESULTS: A total of 447 A4 participants (group A+, 392; normal beta-amyloid group, 55) with a mean (SD) age of 71.
A total of 116 individuals in the A+ group (30% of the A+ group) showed elevated MTL tau (A+T MTL+)
The present study suggests that early tau deposition may follow multiple trajectories during preclinical AD and may involve several cortical regions
The present study suggests that early tau deposition may follow multiple trajectories during preclinical AD and may involve several cortical regions
references:
references:Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
JAMA Neurol.
Published online April 18, 2022.
doi:10.
1001/jamaneurol.
2022.
0676 Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
JAMA Neurol.
Published online April 18, 2022.
doi:10.
1001/jamaneurol.
2022.
0676Leave
a message here
